Eye Diseases, Hereditary clinical trials at University of California Health
2 research studies open to eligible people
open to eligible people ages 8 years and up
The overall goal of this project, co-funded by the Foundation Fighting Blindness and the USHER 1F Collaborative is to characterize the natural history of disease progression in patients with PCDH15 mutations in order to accelerate the development of outcome measures for clinical trials.
Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Advanced Vision Loss (Sirius)
open to eligible people ages 12 years and up
The purpose of this study is to evaluate the efficacy safety and tolerability of QR-421a administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene with advanced vision loss.
at UCSD UCSF
Our lead scientists for Eye Diseases, Hereditary research studies include Jacque Duncan, MD.